astegolimab
mAbexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02918019)
Timeline
Indications
Mechanism of action
- Alcohol sulfotransferaseINHIBITOR
SULT2A1 inhibitor
- IL-33 receptor (ST2)INHIBITOR
IL-33 receptor (ST2) inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594385 ↗
Also known as
- mstt1041a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06462118 | Phase 1 | Jun 17, 2024 | Genentech, Roche |
| NCT05878769 | Phase 3 | Jun 28, 2023 | Roche |
| NCT05595642 | Phase 3 | Dec 30, 2022 | Roche |
| NCT05037929 | Phase 2 | Oct 5, 2021 | Genentech, Roche |
| NCT04386616 | Phase 2 | May 22, 2020 | Genentech |
| NCT03747575 | Phase 2 | Feb 6, 2019 | Genentech |
| NCT03615040 | Phase 2 | Sep 3, 2018 | Genentech, University of Leicester |
| NCT02918019 | Phase 2 | Sep 1, 2016 | Roche |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 5 | 4 | 2 | 2018 |
| Roche | For profit | 5 | 3 | 3 | 2016 |
| University of Leicester | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1